Medicare's Alzheimer's drug coverage policy hinges on patient data.
TL;DR Summary
Medicare will cover the cost of fully approved Alzheimer's disease therapies for patients, but only if their doctors submit data on their treatment to a nationwide registry. This decision comes after the approval of Biogen's controversial Alzheimer's drug, Aduhelm, which has faced criticism for its high cost and questionable efficacy.
- Medicare Will Pay for Alzheimer's Therapies, but With a Big Requirement Barron's
- Medicare to cover Alzheimer’s drug class that includes Leqembi The Washington Post
- US to require patient data for payment of Leqembi, similar Alzheimer's drugs Reuters
- CMS plans to cover new Alzheimer's drugs after full FDA approval FierceHealthcare
- Medicare holds firm on Alzheimer's drug coverage policy STAT
Reading Insights
Total Reads
0
Unique Readers
9
Time Saved
0 min
vs 1 min read
Condensed
33%
75 → 50 words
Want the full story? Read the original article
Read on Barron's